lenalidomide has been researched along with Abnormalities, Autosome in 73 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (17.81) | 29.6817 |
| 2010's | 48 (65.75) | 24.3611 |
| 2020's | 12 (16.44) | 2.80 |
| Authors | Studies |
|---|---|
| Aul, C; Bock, O; Buesche, G; Ebert, BL; Ganser, A; Germing, U; Giagounidis, A; Göhring, G; Kreipe, H; Ribezzo, F; Schlegelberger, B; Schneider, RK; Teoman, H | 1 |
| Bashir, Q; Bassett, R; Champlin, RE; Gaballa, MR; Kaufman, GP; Kebriaei, P; Lee, HC; Lin, P; Ma, J; Manasanch, EE; Murphy, R; Nieto, Y; Orlowski, RZ; Pasvolsky, O; Patel, KK; Qazilbash, MH; Ramdial, J; Rauf, M; Rezvani, K; Saini, N; Shpall, EJ; Srour, SA; Tang, G; Tanner, MR; Thomas, SK; Ullah, MR; Weber, DM | 1 |
| Hanamura, I | 1 |
| Bashir, Q; Champlin, RE; Kebriaei, P; Lee, HC; Masood, A; Milton, DR; Nieto, Y; Orlowski, RZ; Pasvolsky, O; Patel, KK; Qazilbash, MH; Ramdial, J; Rauf, M; Saini, N; Shpall, EJ; Srour, S; Tang, G; Tanner, MR; Thomas, SK; Weber, DM | 1 |
| Chng, WJ; Dash, AB; Dimopoulos, MA; Iida, S; Kumar, SK; Labotka, R; Lonial, S; Moreau, P; Morgan, GJ; Rajkumar, SV; Suryanarayan, K; Twumasi-Ankrah, P; Villarreal, M; Vorog, A; Zhang, X | 1 |
| Bashir, Q; Champlin, RE; Gaballa, MR; Kebriaei, P; Lee, HC; Lin, P; Masood, A; Milton, DR; Nieto, Y; Orlowski, RZ; Pasvolsky, O; Patel, KK; Qazilbash, MH; Ramdial, J; Saini, N; Sami, SS; Shpall, EJ; Srour, S; Tang, G; Tanner, MR; Thomas, SK; Weber, DM | 1 |
| Aoki, Y; Minehata, K; Motegi, Y; Uno, S | 1 |
| Furihata, H; Imai, Y; Kosako, H; Miyakawa, T; Nagaoka, K; Nagasaka, T; Nishino, K; Sawasaki, T; Shibata, N; Shoya, Y; Tanokura, M; Taya, A; Usui, M; Yamanaka, S; Yanagihara, Y; Yoshida, S | 1 |
| Bashir, Q; Champlin, RE; Ghanem, S; Kebriaei, P; Lee, HC; Lin, P; Masood, A; Milton, DR; Nieto, Y; Orlowski, RZ; Pasvolsky, O; Patel, KK; Qazilbash, MH; Ramdial, J; Saini, N; Shpall, EJ; Srour, S; Tanner, MR; Thomas, SK; Weber, DM | 1 |
| Dialoupi, I; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Fotiou, D; Gakiopoulou, H; Gavriatopoulou, M; Kanellias, N; Kastritis, E; Kostopoulos, I; Manios, E; Migkou, M; Ntalianis, A; Ntanasis-Stathopoulos, I; Papadopoulou, E; Papanikolaou, A; Papanota, AM; Psimenou, E; Roussou, M; Stamatelopoulos, K; Terpos, E; Tselegkidi, MI; Tsitsilonis, O; Ziogas, DC | 1 |
| Avet-Loiseau, H; Bahlis, NJ; Berg, D; Dash, AB; Di Bacco, A; Li, B; Lin, J; Moreau, P; Richardson, PG; Shen, L; Zhang, J | 1 |
| Alameda, D; Alignani, D; Bargay, J; Blade, J; Burgos, L; Calasanz, MJ; Cedena, MT; Celay, J; Cordón, L; de la Rubia, J; Flores-Montero, J; Fresquet, V; Garcés, JJ; Garcia-Sanz, R; Goicoechea, I; Gutierrez, NC; Hernandez, MT; Krsnik, I; Lahuerta, JJ; Lara-Astiaso, D; Martin-Sanchez, J; Martinez-Climent, JA; Martinez-Lopez, J; Martinez-Martinez, R; Mateos, MV; Moraleda, JM; Orfao, A; Oriol, A; Paiva, B; Palomera, L; Puig, N; Ramos, MM; Rios, R; Rodriguez, I; Rodriguez, S; Rosiñol, L; San Miguel, J; Sarra, J; Sarvide, S; Vidriales, MB; Vilas-Zornoza, A | 1 |
| Antonioli, E; Barilà, G; Bonalumi, A; Buda, G; Cavo, M; Cea, M; di Giovanni Bezzi, C; Dozza, L; Furlan, A; Mancuso, K; Martello, M; Marzocchi, G; Pantani, L; Petrini, M; Quaresima, M; Rizzello, I; Rocchi, S; Scalese, M; Staderini, M; Tacchetti, P; Zamagni, E | 1 |
| Chen, WM; Fu, ZZ; Hu, Y; Huang, XJ; Huang, ZX; Jin, FY; Li, XL; Liao, AJ; Liu, H; Lu, J; Meng, FY; Wang, GM; Wang, XM; Yang, GZ; Zhang, X; Zhong, YP; Zhou, JF | 1 |
| Avet-Loiseau, H; Bahlis, NJ; Ben-Yehuda, D; Berg, D; Cavo, M; Chng, WJ; di Bacco, A; Esseltine, DL; Ganly, P; Kumar, S; Langer, C; Lin, J; Masszi, T; Moreau, P; Nagler, A; Palumbo, A; Pluta, A; Pour, L; Rajkumar, SV; Richardson, PG; San-Miguel, J; van de Velde, H; Viterbo, L | 1 |
| Ebert, BL; Fenaux, P; List, A | 1 |
| Ando, K; Aoyama, Y; Kawada, H; Kitamura, Y; Nakamura, Y; Ogawa, Y; Suzuki, R; Warita, T | 1 |
| Fujinami, H; Iida, S; Ishida, T; Ito, A; Kinoshita, S; Komatsu, H; Kusumoto, S; Marumo, Y; Masaki, A; Narita, T; Oshima, Y; Ri, M; Sasaki, H; Tachita, T; Totani, H; Yoshida, T | 1 |
| Chang, C; He, Q; Li, X; Wu, L; Xu, F; Zhang, Z | 1 |
| Abdallah, AO; Bailey, C; Barlogie, B; Chauhan, N; Cottler-Fox, M; Crowley, J; Epstein, J; Heuck, CJ; Hoering, A; Johann, D; Muzaffar, J; Petty, N; Rosenthal, A; Sawyer, J; Sexton, R; Singh, Z; Usmani, SZ; van Rhee, F; Waheed, S; Yaccoby, S | 1 |
| Blau, IW; Böhme, A; Braulke, F; Brümmendorf, TH; Bug, G; Detken, S; Ganster, C; Germing, U; Giagounidis, AA; Götze, K; Haase, D; Hofmann, WK; Jentsch-Ullrich, K; Jung, K; Lübbert, M; Metz, M; Müller-Thomas, C; Ottmann, O; Pfeiffer, S; Platzbecker, U; Schafhausen, P; Schanz, J; Schlenk, RF; Schmidt, B; Seraphin, J; Shirneshan, K; Stadler, M; Trümper, L | 1 |
| Bao, L; Huang, X; Jiang, Q; Lai, Y; Liu, Y; Lu, J; Lu, X; Qin, Y; Zhao, X | 1 |
| Greenberg, AJ; Jelinek, DF; Kumar, SK; Rajkumar, SV; Walters, DK | 1 |
| Eom, HS; Jo, DY; Jun, HJ; Kim, JS; Kim, K; Kim, KH; Kim, SH; Kim, SJ; Kim, YS; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Min, CK; Moon, JH; Mun, YC; Park, SK; Ryoo, HM; Suh, C; Voelter, V; Yoon, SS | 1 |
| Leleu, X; Mateos, MV; Palumbo, A; San Miguel, JF | 1 |
| Aoyama, Y; Furukawa, Y; Harada, N; Kumura, T; Manabe, M; Mugitani, A; Ohta, T; Okita, J; Tarakuwa, T | 1 |
| Bird, J; Bowcock, S; Cook, G; Davies, F; Lai, M; Low, E; Morgan, G; Owen, R; Pratt, G; Rabin, N; Snowden, J; Wechalaker, A; Yong, K | 1 |
| Abe, Y; Hamano, A; Hattori, Y; Miyazaki, K; Nakagawa, Y; Sekine, R; Shingaki, S; Suzuki, K; Tsukada, N | 1 |
| Hahn-Ast, C; Kanz, L; Oehrlein, K; Rendl, C; Weisel, K; Zago, M | 1 |
| Ise, M; Kumagai, K; Sakai, C; Tsujimura, H | 1 |
| Borthakur, G; Cortes, J; Daver, N; Jabbour, E; Kadia, T; Kantarjian, H; Newberry, K; Pemmaraju, N; Pierce, S; Ravandi, F; Sasaki, K; Verstovsek, S; Wang, X; Zhou, L | 1 |
| Braulke, F; Ganster, C; Haase, D; Platzbecker, U; Salinas-Riester, G; Schanz, J; Shirneshan, K | 1 |
| Al, MJ; Armstrong, N; Blommestein, HM; Deshpande, S; Kleijnen, J; Noake, C; Riemsma, R; Ryder, S; Severens, JL; Worthy, G | 1 |
| Aschauer, G; Burgstaller, S; Fiegl, M; Fridrik, M; Girschikofsky, M; Greil, R; Keil, F; Linkesch, W; Nösslinger, T; Petzer, A; Stauder, R | 1 |
| Bahlo, J; Bergmann, M; Binder, M; Böttcher, S; Cramer, P; Döhner, H; Dreyling, M; Eichhorst, B; Fink, AM; Fischer, K; Fischer, N; Gross-Ophoff, C; Hallek, M; Kluth, S; Kneba, M; Kreuzer, KA; Langerbeins, P; Maurer, C; Pflug, N; Rhein, C; Stilgenbauer, S; Tausch, E; Wendtner, CM | 1 |
| Berkova, Z; Champlin, RE; Cleeland, C; Feng, L; Mendoza, TR; Orlowski, RZ; Qazilbash, MH; Shah, JJ; Thomas, SK; Wang, M; Weber, DM | 1 |
| Anderson, KC; Attal, M; Avet-Loiseau, H; Bladé, J; Caers, J; Chng, WJ; Durie, BG; Einsele, H; Goldschmidt, H; Hillengass, J; Kyle, RA; Lonial, S; Mateos, MV; Moreau, P; Orlowski, R; Palumbo, A; San Miguel, J; Siegel, D; Sonneveld, P; Usmani, S; van de Donk, NW | 1 |
| Chen, M; Dong, B; Dong, T; Guan, P; Li, J; Liu, T; Ma, H; Niu, T; Pan, L; Shuai, X; Valencia, CA; Wang, F; Wu, Y; Xiang, B; Xie, L; Zhang, L; Zhu, H; Zou, X | 1 |
| Abbasi, T; Bejar, R; Chang, M; Cogle, CR; Drusbosky, L; Hawkins, KE; Kumar, A; Lamba, JK; Mallo, M; Martuscello, R; Medina, C; Sekeres, MA; Singh, NK; Sole, F; Vali, S | 1 |
| Ando, T; Kimura, S; Kizuka, H; Kojima, K; Kubota, Y; Kusaba, K; Nishioka, A; Sano, H; Shindo, T; Ureshino, H | 1 |
| Nohgawa, M; Oka, S; Ono, K | 1 |
| Bergsagel, PL; Buadi, F; Dalton, RJ; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kapoor, P; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Mikhael, JR; Rajkumar, SV; Reeder, CB; Roy, V; Russell, SJ; Stewart, AK; Witzig, TE; Zeldenrust, SR | 1 |
| Bahlis, NJ; Bruyere, H; Chang, H; Chen, C; Fu, T; Horsman, DE; Mansoor, A; Masih-Khan, E; Reece, D; Roland, B; Song, KW; Stewart, DA; Trieu, Y | 1 |
| Abruzzo, L; Borthakur, G; Bueso-Ramos, C; Faderl, S; Garcia-Manero, G; Issa, JP; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F; Shan, J | 1 |
| Mateos, MV; San-Miguel, JF | 1 |
| Attal, M; Avet-Loiseau, H; Belhadj, K; Dorvaux, V; Fermand, JP; Garderet, L; Hulin, C; Minvielle, S; Moreau, P; Soulier, J; Yakoub-Agha, I | 1 |
| Beksac, M; Bladé, J; Boccadoro, M; Cavenagh, J; Cavo, M; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Harousseau, JL; Hess, U; Ketterer, N; Kropff, M; Ludwig, H; Mendeleeva, L; Morgan, G; Palumbo, A; Plesner, T; San Miguel, J; Shpilberg, O; Sondergeld, P; Sonneveld, P; Zweegman, S | 1 |
| Afable, M; Cuthbertson, D; Ganetsky, R; Ganetzky, R; Latham, D; List, AF; Loughran, TP; Maciejewski, JP; Paquette, R; Paulic, K; Saba, HI; Sekeres, MA | 1 |
| Hoffman, M; Mittelman, M; Neumann, D; Oster, HS | 1 |
| Christoulas, D; Dimopoulos, MA; Efstathiou, E; Gavriatopoulou, M; Gkotzamanidou, M; Iakovaki, M; Kastritis, E; Matsouka, C; Migkou, M; Mparmparoussi, D; Roussou, M; Terpos, E | 1 |
| Chang, H; Chen, C; Jiang, A; Qi, C; Reece, D; Trieu, Y | 1 |
| Alici, E; Gahrton, G; Jansson, M; Nahi, H; Sutlu, T | 1 |
| Goldschmidt, H; Hielscher, T; Hillengass, J; Ho, AD; Hose, D; Jauch, A; Klein, U; Neben, K; Raab, MS; Seckinger, A | 1 |
| Astermark, J; Dufva, IH; Dybedal, I; Ejerblad, E; Garelius, H; Grønbæk, K; Hellström-Lindberg, E; Jädersten, M; Jansson, M; Kjeldsen, L; Lindberg, EH; Linder, O; Möllgård, L; Nilsson, L; Nørgaard, JM; Porwit, A; Saft, L; Treppendahl, MB; Vestergaard, H | 1 |
| Chang, H; Jiang, A; Reece, D | 1 |
| Ahmann, GJ; Callander, NS; Fonseca, R; Greipp, PR; Haug, JL; Henderson, KJ; Jacobus, SJ; Kumar, SK; Rajkumar, SV; Siegel, DS; Uno, H; Van Wier, SA | 1 |
| Bergsagel, PL; Bjorklund, CC; Braggio, E; Bruins, LA; Chang, XB; Fonseca, R; Orlowski, RZ; Schmidt, JE; Shi, CX; Stewart, AK; Van Wier, S; Zhu, YX | 1 |
| Horiike, S; Kuroda, J; Nagoshi, H; Taniwaki, M | 1 |
| Afable, M; Guinta, K; Jankowska, A; Jerez, A; List, AF; Maciejewski, J; Makishima, H; McGraw, KL; O'Keefe, CL; Sekeres, MA; Sugimoto, Y; Szpurka, H; Tiu, R; Traina, F; Visconte, V | 1 |
| Borthakur, G; Chen, Y; Cortes, J; Estrov, Z; Faderl, S; Kantarjian, H; Ravandi, F; Rey, K | 1 |
| Espinal-Witter, R; Geyer, JT; Knowles, DM; Mathew, S; Orazi, A; Racchumi, J; Subramaniyam, S; Verma, S; Wang, YL | 1 |
| Bergsagel, PL; Gutierrez, NC; Mateos, MV; Rajkumar, SV; San Miguel, JF | 1 |
| Li, J; Zhou, DB | 1 |
| Aul, C; Germing, U; Giagounidis, AA; Heinsch, M; Hildebrandt, B; Strupp, C | 1 |
| List, AF | 1 |
| Hess, U | 1 |
| Nimer, SD | 1 |
| Bennett, J; Dewald, G; Feldman, E; Giagounidis, A; Greenberg, P; Knight, R; List, A; Patin, J; Powell, B; Raza, A; Reeder, C; Schmidt, M; Stone, R; Thomas, D; Wride, K; Zeldis, J | 1 |
| Le Beau, MM; Olney, HJ | 1 |
| Goss, TF; Hellström-Lindberg, E; Jädersten, M; Knight, R; List, AF; Schaefer, C; Szende, A; Totten, PJ | 1 |
| List, A; Ortega, J | 1 |
| Da Rocha, A; Eclache, V; Fenaux, P; Le Roux, G | 1 |
18 review(s) available for lenalidomide and Abnormalities, Autosome
| Article | Year |
|---|---|
Multiple myeloma with high-risk cytogenetics and its treatment approach.
Topics: Chromosome Aberrations; Cytogenetic Analysis; Cytogenetics; Humans; Lenalidomide; Multiple Myeloma; Prognosis | 2022 |
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Chromosome Aberrations; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma | 2023 |
A decade of progress in myelodysplastic syndrome with chromosome 5q deletion.
Topics: Animals; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Management; Disease Progression; Drug Development; Genetic Heterogeneity; Genetic Predisposition to Disease; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Prognosis; Treatment Outcome; Tumor Suppressor Protein p53 | 2018 |
Initial treatment of transplant-ineligible patients in multiple myeloma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Chromosome Aberrations; Glucocorticoids; Humans; Immunophenotyping; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Quality of Life; Remission Induction; Thalidomide | 2014 |
der(5;17)(p10;q10) is a recurrent but rare whole-arm translocation in patients with hematological neoplasms: a report of three cases.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosome Banding; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 5; Contraindications; Fatal Outcome; Female; Hematologic Neoplasms; Humans; Karyotype; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Lymphoma, T-Cell, Peripheral; Male; Megakaryocytes; Myelodysplastic Syndromes; Neoplasms, Second Primary; Recurrence; Remission Induction; Thalidomide; Translocation, Genetic | 2014 |
5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).
Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 5; Fatal Outcome; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Translocation, Genetic | 2017 |
How to treat a newly diagnosed young patient with multiple myeloma.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Disease Management; Doxorubicin; Endpoint Determination; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Middle Aged; Molecular Diagnostic Techniques; Multicenter Studies as Topic; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide; Transplantation Conditioning | 2009 |
Current multiple myeloma treatment strategies with novel agents: a European perspective.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Clinical Trials as Topic; Decision Making; Decision Trees; Humans; Kidney Failure, Chronic; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous | 2010 |
The lower risk MDS patient at risk of rapid progression.
Topics: Age Factors; alpha Catenin; Antigens, Differentiation; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Caspase 3; Chromosome Aberrations; Cyclin-Dependent Kinase Inhibitor p15; Cytokines; DNA Methylation; Erythrocyte Transfusion; Female; Ferritins; Fibrosis; Gene Expression Regulation; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Inhibitor of Apoptosis Proteins; Lenalidomide; Leukocyte Count; Lipoproteins, LDL; Lymphoid Enhancer-Binding Factor 1; Male; Microtubule-Associated Proteins; Mutation; Myelodysplastic Syndromes; Platelet Count; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptor Protein-Tyrosine Kinases; Risk Factors; Sex Factors; Survivin; Thalidomide | 2010 |
Clinical impact of chromosomal aberrations in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
Genomic stratification of multiple myeloma treated with novel agents.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Genomics; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide | 2012 |
Cytogenetic and molecular abnormalities in myelodysplastic syndrome.
Topics: Animals; Antineoplastic Agents; Azacitidine; Chromosome Aberrations; Humans; Lenalidomide; Mutation; Myelodysplastic Syndromes; Thalidomide | 2011 |
New advances in the diagnosis and treatment of POEMS syndrome.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Boronic Acids; Bortezomib; Castleman Disease; Chromosome Aberrations; Combined Modality Therapy; Dexamethasone; Disease Management; Drug Therapy, Combination; Genes, Immunoglobulin; Humans; Hypertension, Pulmonary; Lenalidomide; Melphalan; Osteosclerosis; Peripheral Blood Stem Cell Transplantation; Plasma Cells; POEMS Syndrome; Prognosis; Pyrazines; Severity of Illness Index; Symptom Assessment; Thalidomide; Transplantation, Autologous; Vascular Endothelial Growth Factor A | 2013 |
Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS).
Topics: Chromosome Aberrations; Erythroid Cells; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2005 |
[The plasma cell myeloma--molecular pathogenesis and target therapies].
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Communication; Chromosome Aberrations; Gene Expression; Glycoproteins; Growth Inhibitors; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Osteoporosis; Osteoprotegerin; Oxides; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Thalidomide; Time Factors | 2006 |
Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Topics: Anemia, Hypochromic; Azacitidine; Bone Marrow; Chromosome Aberrations; Chromosomes, Human, Pair 5; Erythrocyte Transfusion; Erythropoiesis; Erythropoietin; Gene Deletion; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Thalidomide | 2006 |
Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes.
Topics: Chromosome Aberrations; Chromosomes, Human, Pair 5; Humans; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Thalidomide | 2007 |
Immunomodulatory drugs in the treatment of myelodysplastic syndromes.
Topics: Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Humans; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2007 |
15 trial(s) available for lenalidomide and Abnormalities, Autosome
| Article | Year |
|---|---|
Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boron Compounds; Chromosome Aberrations; Dexamethasone; Gene Expression Regulation, Neoplastic; Glycine; Humans; Lenalidomide; Multiple Myeloma; Mutation; NF-kappa B; Prognosis; Progression-Free Survival; Signal Transduction; Transcriptome; Treatment Outcome | 2020 |
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Chromosome Aberrations; Dexamethasone; Drug Resistance, Neoplasm; Female; Flow Cytometry; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Progression-Free Survival; Treatment Outcome | 2021 |
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Survival Rate | 2021 |
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Chromosome Aberrations; Dexamethasone; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; Female; Glycine; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Proportional Hazards Models; Thalidomide | 2017 |
Low RPS14 expression in MDS without 5q - aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q- patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Apoptosis; Bone Marrow Cells; Chromosome Aberrations; Chromosomes, Human, Pair 5; Disease-Free Survival; Erythroblasts; Female; Gene Expression Regulation; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Ribosomal Proteins; Survival Rate; Thalidomide | 2013 |
Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Chromosome Banding; Female; Follow-Up Studies; Germany; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Thalidomide; Time Factors; Treatment Outcome | 2013 |
Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Mutation; Nitriles; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Thalidomide; Treatment Outcome | 2015 |
Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chromosome Aberrations; Drug Administration Schedule; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Rituximab; Thalidomide; Treatment Outcome | 2016 |
Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Staging; Quality of Life; Thalidomide; Treatment Outcome | 2016 |
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Dexamethasone; Disease-Free Survival; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Middle Aged; Multiple Myeloma; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.
Topics: Aged; Azacitidine; Chromosome Aberrations; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Karyotyping; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Precancerous Conditions; Risk Assessment; Thalidomide; Time Factors; Treatment Outcome; United States | 2010 |
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 5; Female; Gene Expression Regulation, Leukemic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Oncogene Protein p21(ras); Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53; WT1 Proteins | 2011 |
Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone.
Topics: Aged; Antineoplastic Agents; Chromosome Aberrations; Dexamethasone; Female; Gene Expression Profiling; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Analysis; Thalidomide; Treatment Outcome | 2011 |
A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Risk Factors; Thalidomide; Treatment Outcome | 2012 |
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Erythrocyte Transfusion; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Thalidomide | 2006 |
40 other study(ies) available for lenalidomide and Abnormalities, Autosome
| Article | Year |
|---|---|
Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic niche.
Topics: Anemia; Animals; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Macrophages; Mice; Myelodysplastic Syndromes; Thalidomide | 2022 |
KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Retrospective Studies; Translocation, Genetic; Transplantation, Autologous | 2022 |
Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies | 2022 |
Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience.
Topics: Chromosome Aberrations; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Multiple Myeloma; Retrospective Studies; Translocation, Genetic; Transplantation, Autologous | 2023 |
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study.
Topics: Aged; Aged, 80 and over; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; East Asian People; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Product Surveillance, Postmarketing; Thalidomide; Treatment Outcome | 2023 |
Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation.
Topics: Chromosome Aberrations; Female; Hematologic Neoplasms; Humans; Immunomodulating Agents; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Pregnancy; Proteolysis; Proteolysis Targeting Chimera | 2023 |
Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma.
Topics: Adult; Aged; Chromosome Aberrations; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Transplantation, Autologous | 2023 |
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bortezomib; Chromosome Aberrations; Dexamethasone; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Treatment Outcome | 2019 |
[A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Dexamethasone; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Prospective Studies; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome | 2017 |
Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management
Topics: Allografts; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bortezomib; Chromosome Aberrations; Dexamethasone; Disease Management; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Magnetic Resonance Imaging; Melphalan; Multiple Myeloma; Panobinostat; Prognosis; Protease Inhibitors; Risk; Risk Assessment; Salvage Therapy; Transplantation, Autologous | 2018 |
A case of double-refractory multiple myeloma with both the IgH-MMSET fusion protein and the congenital abnormality t(11;22).
Topics: Aged; Bortezomib; Chromosome Aberrations; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 4; Disease Progression; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Lenalidomide; Multiple Myeloma; Oncogene Proteins, Fusion | 2019 |
Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Banding; Combined Modality Therapy; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Recurrence; Retrospective Studies; Salvage Therapy; Translocation, Genetic; Transplantation, Autologous | 2019 |
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Leukemia; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Risk Factors; Thalidomide; Young Adult | 2013 |
CXCR4 is a good survival prognostic indicator in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Chemokine CXCL12; Chromosome Aberrations; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazines; Receptors, CXCR4; Survival Rate; Thalidomide | 2013 |
Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Chromosome Aberrations; Dose-Response Relationship, Drug; Gene Expression; Humans; Immunologic Factors; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Thalidomide; Ubiquitin-Protein Ligases | 2013 |
Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Korea; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Clinical Trials as Topic; Consolidation Chemotherapy; Disease Management; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Remission Induction; Survival Analysis; Thalidomide; United Kingdom | 2014 |
Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Humans; Immunosuppressive Agents; Lenalidomide; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pyrazines; Retrospective Studies; Thalidomide; Time Factors | 2014 |
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Disease Progression; Drug Evaluation; Feasibility Studies; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Sensation Disorders; Thalidomide; Thromboembolism; Transplantation, Autologous | 2014 |
Hepatic extramedullary disease in multiple myeloma with 17p deletion.
Topics: Aneuploidy; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Clone Cells; Dexamethasone; Fatal Outcome; Female; Gene Deletion; Genes, p53; Humans; Incidental Findings; Lenalidomide; Liver; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Multiple Primary; Osteolysis; Proteasome Inhibitors; Pyrazines; Recurrence; Thalidomide; Tumor Suppressor Protein p53; Uterine Neoplasms | 2014 |
Influence of total genomic alteration and chromosomal fragmentation on response to a combination of azacitidine and lenalidomide in a cohort of patients with very high risk MDS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Female; Humans; Kaplan-Meier Estimate; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Proportional Hazards Models; Thalidomide; Tumor Suppressor Protein p53 | 2015 |
Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene.
Topics: Anemia, Macrocytic; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Cost-Benefit Analysis; Health Care Costs; Humans; Lenalidomide; Models, Economic; Myelodysplastic Syndromes; Quality-Adjusted Life Years; Technology Assessment, Biomedical; Thalidomide | 2016 |
Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Angiogenesis Inhibitors; Austria; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Comorbidity; Disease Progression; Erythrocyte Transfusion; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Standard of Care; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Consensus; Cytogenetics; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Risk Factors; Thalidomide; Transplantation, Autologous | 2016 |
Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bortezomib; C-Reactive Protein; Chromosome Aberrations; Chromosomes, Human, Pair 1; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Exosomes; Female; Gene Amplification; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Microarray Analysis; MicroRNAs; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Risk Factors; Thalidomide; Tumor Microenvironment | 2016 |
Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients.
Topics: Chromosome Aberrations; Cohort Studies; Computational Biology; Computer Simulation; Drug Resistance, Neoplasm; Humans; Lenalidomide; Myelodysplastic Syndromes; Protein Interaction Maps; Retrospective Studies; Thalidomide; Treatment Outcome | 2017 |
Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide.
Topics: Aged; Biomarkers, Tumor; Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Janus Kinase 2; Lenalidomide; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Prognosis | 2017 |
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone.
Topics: Adult; Aged; Chromosome Aberrations; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Prognosis; Remission Induction; Retrospective Studies; Risk Assessment; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?
Topics: Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Monosomy; Myelodysplastic Syndromes; Prognosis; Risk; Survival Analysis; Thalidomide | 2009 |
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Proportional Hazards Models; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2010 |
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Pyrazines; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 1; Cohort Studies; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Analysis; Thalidomide; Treatment Outcome | 2010 |
Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 17; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Recurrence; Thalidomide; Translocation, Genetic | 2011 |
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromosome Aberrations; Comparative Genomic Hybridization; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Lenalidomide; Models, Biological; Multiple Myeloma; Peptide Hydrolases; Pyrazines; RNA, Small Interfering; Thalidomide; Ubiquitin-Protein Ligases | 2011 |
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.
Topics: Aged; Aged, 80 and over; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; DNA Methyltransferase 3A; Female; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Polymorphism, Single Nucleotide; Prognosis; Thalidomide | 2012 |
Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosomes, Human, Pair 5; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Janus Kinase 2; Kaplan-Meier Estimate; Karyotyping; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Sequence Deletion; Thalidomide | 2013 |
Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Thalidomide; Treatment Outcome | 2013 |
Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Karyotyping; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Prognosis; Remission Induction; Survival Rate; Thalidomide | 2005 |
Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States.
Topics: Antineoplastic Agents; Blood Transfusion; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Cost-Benefit Analysis; Decision Support Techniques; Erythropoietin; Humans; Lenalidomide; Medical Oncology; Models, Econometric; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Quality-Adjusted Life Years; Recombinant Proteins; Risk Factors; Thalidomide; United States | 2006 |
Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide.
Topics: Antineoplastic Agents; Chromosome Aberrations; Chromosomes, Human, Pair 5; Drug Resistance; Female; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Sequence Deletion; Thalidomide | 2008 |